Aurantiamide acetate

Aurantiamide acetate is a synthetic dipeptide derivative composed of a phenylalanine-benzylamine scaffold with an acetate moiety, studied primarily for its anti-inflammatory and potential neuroprotective properties. Its proposed mechanisms involve modulation of inflammatory signaling pathways and inhibition of P-glycoprotein, a membrane efflux transporter that governs drug bioavailability.

Origin & History

Aurantiamide acetate is a dipeptide derivative with a molecular formula of C27H28N2O4. It is naturally found in plants like Stemona japonica and Viola philippica. The compound is a white to off-white solid that is soluble in DMSO and ethanol.

Historical & Cultural Context

No traditional or historical medicinal uses for aurantiamide acetate are documented in the research. It does not appear in any specific cultural or historical medicinal systems.

Health Benefits

• Potential anti-inflammatory properties as suggested by product literature, though specific targets are not detailed. • Predicted to inhibit P-glycoprotein modestly, which may influence drug absorption and distribution. • Computational predictions suggest CYP enzyme inhibition, indicating possible effects on drug metabolism. • High predicted plasma protein binding could affect drug efficacy and distribution. • Predicted moderate intestinal absorption suggests potential for oral bioavailability.

How It Works

Aurantiamide acetate is predicted to inhibit P-glycoprotein (ABCB1), an ATP-dependent efflux pump on intestinal and blood-brain barrier membranes, potentially increasing intracellular concentrations of co-administered substrates. Computational docking models also suggest inhibitory interactions with CYP3A4 and CYP2C9 enzymes in the hepatic cytochrome P450 system, which could alter the metabolic clearance of numerous drugs. Additionally, proposed anti-inflammatory activity may involve downregulation of NF-κB-mediated pro-inflammatory cytokine expression, though specific receptor binding data remain unpublished.

Scientific Research

There are no human clinical trials or meta-analyses found for aurantiamide acetate. The compound is classified as preclinical in ChEMBL, with no PubMed PMIDs available for human studies.

Clinical Summary

To date, no published randomized controlled trials or peer-reviewed human clinical studies specifically investigate aurantiamide acetate as an isolated supplement ingredient. Available evidence is largely derived from in silico computational predictions, in vitro cell-line assays, and product marketing literature, none of which establish efficacy in human populations. Some preclinical data from related dipeptide analogs suggest modest anti-inflammatory effects at micromolar concentrations in cell culture models, but dose-response relationships in vivo have not been established. The overall evidence base is preliminary, and claims of clinical benefit should be interpreted with significant caution until controlled human trials are conducted.

Nutritional Profile

Aurantiamide acetate is a dipeptide derivative (N-benzoyl-L-phenylalanyl-L-phenylalanine acetate ester) and is not a conventional nutritional ingredient; it does not contribute meaningful macronutrients, micronutrients, vitamins, minerals, or dietary fiber. As a bioactive small molecule (molecular weight ~446.5 g/mol), it is classified under specialized phytochemical/pharmaceutical compounds rather than nutritional categories. It is naturally occurring in plants such as Aegle marmelos and certain Zanthoxylum species, typically present in trace concentrations (microgram-to-milligram range per gram of plant extract). Its primary relevance is pharmacological rather than nutritional: it contains two phenylalanine residues linked by a benzoyl group with an acetate moiety, contributing negligible caloric value at bioactive doses. Bioavailability is predicted to be influenced by high plasma protein binding (estimated >90% based on computational models) and modest P-glycoprotein inhibition, suggesting variable absorption dependent on gut transporter activity. No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists. Protein/amino acid contribution is structurally present (two phenylalanine units) but nutritionally insignificant at typical exposure levels. Fat and carbohydrate content: none intrinsic to the molecule itself.

Preparation & Dosage

No clinically studied dosage ranges or forms are reported, as no human clinical studies have been conducted. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Omega-3 fatty acids, Resveratrol, Green tea extract, Quercetin

Safety & Interactions

No formal human safety trials have been conducted for aurantiamide acetate, making its adverse effect profile largely unknown and its use speculative from a clinical standpoint. Its predicted inhibition of P-glycoprotein raises concern for interactions with drugs such as digoxin, cyclosporine, and certain chemotherapy agents whose bioavailability is regulated by ABCB1 efflux. Predicted CYP3A4 and CYP2C9 inhibition suggests potential interactions with warfarin, statins, benzodiazepines, and other hepatically metabolized medications, which could increase plasma levels and toxicity risk. Pregnant and breastfeeding individuals, as well as those on polypharmacy regimens, should avoid this compound entirely until safety data are available.